Global Anti-tuberculosis Therapeutics Market Insights, Forecast to 2028

TABLE OF CONTENTS

1 Report Business Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
  • 1.2.2 Isoniazid
  • 1.2.3 Rifampin
  • 1.2.4 Ethambutol
  • 1.2.5 Pyrazinamide
  • 1.2.6 Otherr
• 1.3 Market by Application
  • 1.3.1 Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
  • 1.3.2 Hospitals and Clinics
  • 1.3.3 Government Agencies
  • 1.3.4 Non-Profit Organizations
  • 1.3.5 Others
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Anti-tuberculosis Therapeutics Market Perspective (2017-2028)
• 2.2 Anti-tuberculosis Therapeutics Growth Trends by Region
  • 2.2.1 Anti-tuberculosis Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
  • 2.2.2 Anti-tuberculosis Therapeutics Historic Market Size by Region (2017-2022)
  • 2.2.3 Anti-tuberculosis Therapeutics Forecasted Market Size by Region (2023-2028)
• 2.3 Anti-tuberculosis Therapeutics Market Dynamics
  • 2.3.1 Anti-tuberculosis Therapeutics Industry Trends
  • 2.3.2 Anti-tuberculosis Therapeutics Market Drivers
  • 2.3.3 Anti-tuberculosis Therapeutics Market Challenges
  • 2.3.4 Anti-tuberculosis Therapeutics Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Anti-tuberculosis Therapeutics Players by Revenue
  • 3.1.1 Global Top Anti-tuberculosis Therapeutics Players by Revenue (2017-2022)
  • 3.1.2 Global Anti-tuberculosis Therapeutics Revenue Market Share by Players (2017-2022)
• 3.2 Global Anti-tuberculosis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.3 Players Covered: Ranking by Anti-tuberculosis Therapeutics Revenue
• 3.4 Global Anti-tuberculosis Therapeutics Market Concentration Ratio
  • 3.4.1 Global Anti-tuberculosis Therapeutics Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Anti-tuberculosis Therapeutics Revenue in 2021
• 3.5 Anti-tuberculosis Therapeutics Key Players Head office and Area Served
• 3.6 Key Players Anti-tuberculosis Therapeutics Product Solution and Service
• 3.7 Date of Enter into Anti-tuberculosis Therapeutics Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-tuberculosis Therapeutics Breakdown Data by Type

• 4.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Type (2017-2022)
• 4.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Type (2023-2028)

5 Anti-tuberculosis Therapeutics Breakdown Data by Application

• 5.1 Global Anti-tuberculosis Therapeutics Historic Market Size by Application (2017-2022)
• 5.2 Global Anti-tuberculosis Therapeutics Forecasted Market Size by Application (2023-2028)

6 North America

• 6.1 North America Anti-tuberculosis Therapeutics Market Size (2017-2028)
• 6.2 North America Anti-tuberculosis Therapeutics Market Size by Type
  • 6.2.1 North America Anti-tuberculosis Therapeutics Market Size by Type (2017-2022)
  • 6.2.2 North America Anti-tuberculosis Therapeutics Market Size by Type (2023-2028)
  • 6.2.3 North America Anti-tuberculosis Therapeutics Market Share by Type (2017-2028)
• 6.3 North America Anti-tuberculosis Therapeutics Market Size by Application
  • 6.3.1 North America Anti-tuberculosis Therapeutics Market Size by Application (2017-2022)
  • 6.3.2 North America Anti-tuberculosis Therapeutics Market Size by Application (2023-2028)
  • 6.3.3 North America Anti-tuberculosis Therapeutics Market Share by Application (2017-2028)
• 6.4 North America Anti-tuberculosis Therapeutics Market Size by Country
  • 6.4.1 North America Anti-tuberculosis Therapeutics Market Size by Country (2017-2022)
  • 6.4.2 North America Anti-tuberculosis Therapeutics Market Size by Country (2023-2028)
  • 6.4.3 U.S.
  • 6.4.4 Canada

7 Europe

• 7.1 Europe Anti-tuberculosis Therapeutics Market Size (2017-2028)
• 7.2 Europe Anti-tuberculosis Therapeutics Market Size by Type
  • 7.2.1 Europe Anti-tuberculosis Therapeutics Market Size by Type (2017-2022)
  • 7.2.2 Europe Anti-tuberculosis Therapeutics Market Size by Type (2023-2028)
  • 7.2.3 Europe Anti-tuberculosis Therapeutics Market Share by Type (2017-2028)
• 7.3 Europe Anti-tuberculosis Therapeutics Market Size by Application
  • 7.3.1 Europe Anti-tuberculosis Therapeutics Market Size by Application (2017-2022)
  • 7.3.2 Europe Anti-tuberculosis Therapeutics Market Size by Application (2023-2028)
  • 7.3.3 Europe Anti-tuberculosis Therapeutics Market Share by Application (2017-2028)
• 7.4 Europe Anti-tuberculosis Therapeutics Market Size by Country
  • 7.4.1 Europe Anti-tuberculosis Therapeutics Market Size by Country (2017-2022)
  • 7.4.2 Europe Anti-tuberculosis Therapeutics Market Size by Country (2023-2028)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic Countries

8 Asia-Pacific

• 8.1 Asia-Pacific Anti-tuberculosis Therapeutics Market Size (2017-2028)
• 8.2 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Type
  • 8.2.1 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Type (2017-2022)
  • 8.2.2 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Type (2023-2028)
  • 8.2.3 Asia-Pacific Anti-tuberculosis Therapeutics Market Share by Type (2017-2028)
• 8.3 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Application
  • 8.3.1 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Application (2017-2022)
  • 8.3.2 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Application (2023-2028)
  • 8.3.3 Asia-Pacific Anti-tuberculosis Therapeutics Market Share by Application (2017-2028)
• 8.4 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Region
  • 8.4.1 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Region (2017-2022)
  • 8.4.2 Asia-Pacific Anti-tuberculosis Therapeutics Market Size by Region (2023-2028)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Anti-tuberculosis Therapeutics Market Size (2017-2028)
• 9.2 Latin America Anti-tuberculosis Therapeutics Market Size by Type
  • 9.2.1 Latin America Anti-tuberculosis Therapeutics Market Size by Type (2017-2022)
  • 9.2.2 Latin America Anti-tuberculosis Therapeutics Market Size by Type (2023-2028)
  • 9.2.3 Latin America Anti-tuberculosis Therapeutics Market Share by Type (2017-2028)
• 9.3 Latin America Anti-tuberculosis Therapeutics Market Size by Application
  • 9.3.1 Latin America Anti-tuberculosis Therapeutics Market Size by Application (2017-2022)
  • 9.3.2 Latin America Anti-tuberculosis Therapeutics Market Size by Application (2023-2028)
  • 9.3.3 Latin America Anti-tuberculosis Therapeutics Market Share by Application (2017-2028)
• 9.4 Latin America Anti-tuberculosis Therapeutics Market Size by Country
  • 9.4.1 Latin America Anti-tuberculosis Therapeutics Market Size by Country (2017-2022)
  • 9.4.2 Latin America Anti-tuberculosis Therapeutics Market Size by Country (2023-2028)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Anti-tuberculosis Therapeutics Market Size (2017-2028)
• 10.2 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Type
  • 10.2.1 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Type (2017-2022)
  • 10.2.2 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Type (2023-2028)
  • 10.2.3 Middle East & Africa Anti-tuberculosis Therapeutics Market Share by Type (2017-2028)
• 10.3 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Application
  • 10.3.1 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Application (2017-2022)
  • 10.3.2 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Application (2023-2028)
  • 10.3.3 Middle East & Africa Anti-tuberculosis Therapeutics Market Share by Application (2017-2028)
• 10.4 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Country
  • 10.4.1 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Country (2017-2022)
  • 10.4.2 Middle East & Africa Anti-tuberculosis Therapeutics Market Size by Country (2023-2028)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Lupin
  • 11.1.1 Lupin Company Details
  • 11.1.2 Lupin Business Overview
  • 11.1.3 Lupin Anti-tuberculosis Therapeutics Introduction
  • 11.1.4 Lupin Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.1.5 Lupin Recent Developments
• 11.2 Macleods Pharmaceuticals
  • 11.2.1 Macleods Pharmaceuticals Company Details
  • 11.2.2 Macleods Pharmaceuticals Business Overview
  • 11.2.3 Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Introduction
  • 11.2.4 Macleods Pharmaceuticals Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.2.5 Macleods Pharmaceuticals Recent Developments
• 11.3 Otsuka Pharmaceutical
  • 11.3.1 Otsuka Pharmaceutical Company Details
  • 11.3.2 Otsuka Pharmaceutical Business Overview
  • 11.3.3 Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Introduction
  • 11.3.4 Otsuka Pharmaceutical Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.3.5 Otsuka Pharmaceutical Recent Developments
• 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Anti-tuberculosis Therapeutics Introduction
  • 11.4.4 Johnson & Johnson Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.4.5 Johnson & Johnson Recent Developments
• 11.5 Pfizer
  • 11.5.1 Pfizer Company Details
  • 11.5.2 Pfizer Business Overview
  • 11.5.3 Pfizer Anti-tuberculosis Therapeutics Introduction
  • 11.5.4 Pfizer Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.5.5 Pfizer Recent Developments
• 11.6 Novartis
  • 11.6.1 Novartis Company Details
  • 11.6.2 Novartis Business Overview
  • 11.6.3 Novartis Anti-tuberculosis Therapeutics Introduction
  • 11.6.4 Novartis Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.6.5 Novartis Recent Developments
• 11.7 Abbott
  • 11.7.1 Abbott Company Details
  • 11.7.2 Abbott Business Overview
  • 11.7.3 Abbott Anti-tuberculosis Therapeutics Introduction
  • 11.7.4 Abbott Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.7.5 Abbott Recent Developments
• 11.8 AstraZeneca
  • 11.8.1 AstraZeneca Company Details
  • 11.8.2 AstraZeneca Business Overview
  • 11.8.3 AstraZeneca Anti-tuberculosis Therapeutics Introduction
  • 11.8.4 AstraZeneca Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.8.5 AstraZeneca Recent Developments
• 11.9 Bayer
  • 11.9.1 Bayer Company Details
  • 11.9.2 Bayer Business Overview
  • 11.9.3 Bayer Anti-tuberculosis Therapeutics Introduction
  • 11.9.4 Bayer Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.9.5 Bayer Recent Developments
• 11.10 Eli Lilly
  • 11.10.1 Eli Lilly Company Details
  • 11.10.2 Eli Lilly Business Overview
  • 11.10.3 Eli Lilly Anti-tuberculosis Therapeutics Introduction
  • 11.10.4 Eli Lilly Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.10.5 Eli Lilly Recent Developments
• 11.11 GlaxoSmithKline
  • 11.11.1 GlaxoSmithKline Company Details
  • 11.11.2 GlaxoSmithKline Business Overview
  • 11.11.3 GlaxoSmithKline Anti-tuberculosis Therapeutics Introduction
  • 11.11.4 GlaxoSmithKline Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.11.5 GlaxoSmithKline Recent Developments
• 11.12 Merck
  • 11.12.1 Merck Company Details
  • 11.12.2 Merck Business Overview
  • 11.12.3 Merck Anti-tuberculosis Therapeutics Introduction
  • 11.12.4 Merck Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.12.5 Merck Recent Developments
• 11.13 Sanofi
  • 11.13.1 Sanofi Company Details
  • 11.13.2 Sanofi Business Overview
  • 11.13.3 Sanofi Anti-tuberculosis Therapeutics Introduction
  • 11.13.4 Sanofi Revenue in Anti-tuberculosis Therapeutics Business (2017-2022)
  • 11.13.5 Sanofi Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Author Details
• 13.3 Disclaimer

• Table 1. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
• Table 2. Key Players of Isoniazid
• Table 3. Key Players of Rifampin
• Table 4. Key Players of Ethambutol
• Table 5. Key Players of Pyrazinamide
• Table 6. Key Players of Otherr
• Table 7. Global Anti-tuberculosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
• Table 8. Global Anti-tuberculosis Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
• Table 9. Global Anti-tuberculosis Therapeutics Market Size by Region (2017-2022) & (US$ Million)
• Table 10. Global Anti-tuberculosis Therapeutics Market Share by Region (2017-2022)
• Table 11. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
• Table 12. Global Anti-tuberculosis Therapeutics Market Share by Region (2023-2028)
• Table 13. Anti-tuberculosis Therapeutics Market Trends
• Table 14. Anti-tuberculosis Therapeutics Market Drivers
• Table 15. Anti-tuberculosis Therapeutics Market Challenges
• Table 16. Anti-tuberculosis Therapeutics Market Restraints
• Table 17. Global Anti-tuberculosis Therapeutics Revenue by Players (2017-2022) & (US$ Million)
• Table 18. Global Anti-tuberculosis Therapeutics Revenue Share by Players (2017-2022)
• Table 19. Global Top Anti-tuberculosis Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tuberculosis Therapeutics as of 2021)
• Table 20. Ranking of Global Top Anti-tuberculosis Therapeutics Companies by Revenue (US$ Million) in 2021
• Table 21. Global 5 Largest Players Market Share by Anti-tuberculosis Therapeutics Revenue (CR5 and HHI) & (2017-2022)
• Table 22. Key Players Headquarters and Area Served
• Table 23. Key Players Anti-tuberculosis Therapeutics Product Solution and Service
• Table 24. Date of Enter into Anti-tuberculosis Therapeutics Market
• Table 25. Mergers & Acquisitions, Expansion Plans
• Table 26. Global Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 27. Global Anti-tuberculosis Therapeutics Revenue Market Share by Type (2017-2022)
• Table 28. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
• Table 29. Global Anti-tuberculosis Therapeutics Revenue Market Share by Type (2023-2028)
• Table 30. Global Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 31. Global Anti-tuberculosis Therapeutics Revenue Share by Application (2017-2022)
• Table 32. Global Anti-tuberculosis Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
• Table 33. Global Anti-tuberculosis Therapeutics Revenue Share by Application (2023-2028)
• Table 34. North America Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 35. North America Anti-tuberculosis Therapeutics Market Size by Type (2023-2028) & (US$ Million)
• Table 36. North America Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 37. North America Anti-tuberculosis Therapeutics Market Size by Application (2023-2028) & (US$ Million)
• Table 38. North America Anti-tuberculosis Therapeutics Market Size by Country (2017-2022) & (US$ Million)
• Table 39. North America Anti-tuberculosis Therapeutics Market Size by Country (2023-2028) & (US$ Million)
• Table 40. Europe Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 41. Europe Anti-tuberculosis Therapeutics Market Size by Type (2023-2028) & (US$ Million)
• Table 42. Europe Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 43. Europe Anti-tuberculosis Therapeutics Market Size by Application (2023-2028) & (US$ Million)
• Table 44. Europe Anti-tuberculosis Therapeutics Market Size by Country (2017-2022) & (US$ Million)
• Table 45. Europe Anti-tuberculosis Therapeutics Market Size by Country (2023-2028) & (US$ Million)
• Table 46. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 47. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Type (2023-2028) & (US$ Million)
• Table 48. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 49. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Application (2023-2028) & (US$ Million)
• Table 50. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Region (2017-2022) & (US$ Million)
• Table 51. Asia Pacific Anti-tuberculosis Therapeutics Market Size by Region (2023-2028) & (US$ Million)
• Table 52. Latin America Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 53. Latin America Anti-tuberculosis Therapeutics Market Size by Type (2023-2028) & (US$ Million)
• Table 54. Latin America Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 55. Latin America Anti-tuberculosis Therapeutics Market Size by Application (2023-2028) & (US$ Million)
• Table 56. Latin America Anti-tuberculosis Therapeutics Market Size by Country (2017-2022) & (US$ Million)
• Table 57. Latin America Anti-tuberculosis Therapeutics Market Size by Country (2023-2028) & (US$ Million)
• Table 58. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Type (2017-2022) & (US$ Million)
• Table 59. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Type (2023-2028) & (US$ Million)
• Table 60. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Application (2017-2022) & (US$ Million)
• Table 61. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Application (2023-2028) & (US$ Million)
• Table 62. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Country (2017-2022) & (US$ Million)
• Table 63. Middle East and Africa Anti-tuberculosis Therapeutics Market Size by Country (2023-2028) & (US$ Million)
• Table 64. Lupin Company Details
• Table 65. Lupin Business Overview
• Table 66. Lupin Anti-tuberculosis Therapeutics Product
• Table 67. Lupin Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 68. Lupin Recent Developments
• Table 69. Macleods Pharmaceuticals Company Details
• Table 70. Macleods Pharmaceuticals Business Overview
• Table 71. Macleods Pharmaceuticals Anti-tuberculosis Therapeutics Product
• Table 72. Macleods Pharmaceuticals Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 73. Macleods Pharmaceuticals Recent Developments
• Table 74. Otsuka Pharmaceutical Company Details
• Table 75. Otsuka Pharmaceutical Business Overview
• Table 76. Otsuka Pharmaceutical Anti-tuberculosis Therapeutics Product
• Table 77. Otsuka Pharmaceutical Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 78. Otsuka Pharmaceutical Recent Developments
• Table 79. Johnson & Johnson Company Details
• Table 80. Johnson & Johnson Business Overview
• Table 81. Johnson & Johnson Anti-tuberculosis Therapeutics Product
• Table 82. Johnson & Johnson Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 83. Johnson & Johnson Recent Developments
• Table 84. Pfizer Company Details
• Table 85. Pfizer Business Overview
• Table 86. Pfizer Anti-tuberculosis Therapeutics Product
• Table 87. Pfizer Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 88. Pfizer Recent Developments
• Table 89. Novartis Company Details
• Table 90. Novartis Business Overview
• Table 91. Novartis Anti-tuberculosis Therapeutics Product
• Table 92. Novartis Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 93. Novartis Recent Developments
• Table 94. Abbott Company Details
• Table 95. Abbott Business Overview
• Table 96. Abbott Anti-tuberculosis Therapeutics Product
• Table 97. Abbott Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 98. Abbott Recent Developments
• Table 99. AstraZeneca Company Details
• Table 100. AstraZeneca Business Overview
• Table 101. AstraZeneca Anti-tuberculosis Therapeutics Product
• Table 102. AstraZeneca Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 103. AstraZeneca Recent Developments
• Table 104. Bayer Company Details
• Table 105. Bayer Business Overview
• Table 106. Bayer Anti-tuberculosis Therapeutics Product
• Table 107. Bayer Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 108. Bayer Recent Developments
• Table 109. Eli Lilly Company Details
• Table 110. Eli Lilly Business Overview
• Table 111. Eli Lilly Anti-tuberculosis Therapeutics Product
• Table 112. Eli Lilly Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 113. Eli Lilly Recent Developments
• Table 114. GlaxoSmithKline Company Details
• Table 115. GlaxoSmithKline Business Overview
• Table 116. GlaxoSmithKline Anti-tuberculosis Therapeutics Product
• Table 117. GlaxoSmithKline Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 118. GlaxoSmithKline Recent Developments
• Table 119. Merck Company Details
• Table 120. Merck Business Overview
• Table 121. Merck Anti-tuberculosis Therapeutics Product
• Table 122. Merck Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 123. Merck Recent Developments
• Table 124. Sanofi Company Details
• Table 125. Sanofi Business Overview
• Table 126. Sanofi Anti-tuberculosis Therapeutics Product
• Table 127. Sanofi Revenue in Anti-tuberculosis Therapeutics Business (2017-2022) & (US$ Million)
• Table 128. Sanofi Recent Developments
• Table 129. Research Programs/Design for This Report
• Table 130. Key Data Information from Secondary Sources
• Table 131. Key Data Information from Primary Sources

List of Figures

• Figure 1. Global Anti-tuberculosis Therapeutics Market Share by Type: 2021 VS 2028
• Figure 2. Isoniazid Features
• Figure 3. Rifampin Features
• Figure 4. Ethambutol Features
• Figure 5. Pyrazinamide Features
• Figure 6. Otherr Features
• Figure 7. Global Anti-tuberculosis Therapeutics Market Share by Application: 2021 VS 2028
• Figure 8. Hospitals and Clinics Case Studies
• Figure 9. Government Agencies Case Studies
• Figure 10. Non-Profit Organizations Case Studies
• Figure 11. Others Case Studies
• Figure 12. Anti-tuberculosis Therapeutics Report Years Considered
• Figure 13. Global Anti-tuberculosis Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
• Figure 14. Global Anti-tuberculosis Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
• Figure 15. Global Anti-tuberculosis Therapeutics Market Share by Region: 2021 VS 2028
• Figure 16. Global Anti-tuberculosis Therapeutics Market Share by Players in 2021
• Figure 17. Global Top Anti-tuberculosis Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tuberculosis Therapeutics as of 2021)
• Figure 18. The Top 10 and 5 Players Market Share by Anti-tuberculosis Therapeutics Revenue in 2021
• Figure 19. North America Anti-tuberculosis Therapeutics Market Size YoY (2017-2028) & (US$ Million)
• Figure 20. North America Anti-tuberculosis Therapeutics Market Size Market Share by Type (2017-2028)
• Figure 21. North America Anti-tuberculosis Therapeutics Market Size Market Share by Application (2017-2028)
• Figure 22. North America Anti-tuberculosis Therapeutics Market Size Share by Country (2017-2028)
• Figure 23. United States Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 24. Canada Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 25. Europe Anti-tuberculosis Therapeutics Market Size YoY (2017-2028) & (US$ Million)
• Figure 26. Europe Anti-tuberculosis Therapeutics Market Size Market Share by Type (2017-2028)
• Figure 27. Europe Anti-tuberculosis Therapeutics Market Size Market Share by Application (2017-2028)
• Figure 28. Europe Anti-tuberculosis Therapeutics Market Size Share by Country (2017-2028)
• Figure 29. Germany Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 30. France Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 31. U.K. Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 32. Italy Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 33. Russia Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 34. Nordic Countries Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 35. Asia-Pacific Anti-tuberculosis Therapeutics Market Size YoY (2017-2028) & (US$ Million)
• Figure 36. Asia Pacific Anti-tuberculosis Therapeutics Market Size Market Share by Type (2017-2028)
• Figure 37. Asia Pacific Anti-tuberculosis Therapeutics Market Size Market Share by Application (2017-2028)
• Figure 38. Asia Pacific Anti-tuberculosis Therapeutics Market Size Share by Region (2017-2028)
• Figure 39. China Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 40. Japan Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 41. South Korea Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 42. Southeast Asia Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 43. India Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 44. Australia Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)

List of Figures

• Figure 45. Latin America Anti-tuberculosis Therapeutics Market Size YoY (2017-2028) & (US$ Million)
• Figure 46. Latin America Anti-tuberculosis Therapeutics Market Size Market Share by Type (2017-2028)
• Figure 47. Latin America Anti-tuberculosis Therapeutics Market Size Market Share by Application (2017-2028)
• Figure 48. Latin America Anti-tuberculosis Therapeutics Market Size Share by Country (2017-2028)
• Figure 49. Mexico Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 50. Brazil Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 51. Middle East & Africa Anti-tuberculosis Therapeutics Market Size YoY (2017-2028) & (US$ Million)
• Figure 52. Middle East and Africa Anti-tuberculosis Therapeutics Market Size Market Share by Type (2017-2028)
• Figure 53. Middle East and Africa Anti-tuberculosis Therapeutics Market Size Market Share by Application (2017-2028)
• Figure 54. Middle East and Africa Anti-tuberculosis Therapeutics Market Size Share by Country (2017-2028)
• Figure 55. Turkey Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 56. Saudi Arabia Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 57. UAE Anti-tuberculosis Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
• Figure 58. Lupin Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 59. Macleods Pharmaceuticals Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 60. Otsuka Pharmaceutical Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 61. Johnson & Johnson Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 62. Pfizer Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 63. Novartis Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 64. Abbott Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 65. AstraZeneca Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 66. Bayer Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 67. Eli Lilly Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 68. GlaxoSmithKline Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 69. Merck Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 70. Sanofi Revenue Growth Rate in Anti-tuberculosis Therapeutics Business (2017-2022)
• Figure 71. Bottom-up and Top-down Approaches for This Report
• Figure 72. Data Triangulation
• Figure 73. Key Executives Interviewed